Infigratinib and AZD4547 had shown activity in lung squamous cell carcinoma with FGFR1 amplification (Zhang et al. 2012, Nogova et al. 2017, Paik et al. 2017). The gene discussed is FGFR1; the disease is squamous cell lung carcinoma.